Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco

被引:30
作者
Almquist, KC
McLean, MD
Niu, YQ
Byrne, G
Olea-Popelka, FC
Murrant, C
Barclay, J
Hall, JC [1 ]
机构
[1] Univ Guelph, Dept Environm Biol, Guelph, ON N1G 2W1, Canada
[2] Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
toxin; clearance; tobacco; scFv;
D O I
10.1016/j.vaccine.2005.11.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Botulinum neurotoxins (BoNTs) are the most poisonous substances known and are thus classified as high-risk threats for use as bioterror agents. To examine the potential of transgenic plants as bioreactors for the production of BoNT antidotes, we transformed tobacco with an optimized, synthetic gene encoding a botulinum neurotoxin A (BoNT/A) neutralizing single-chain Fv (scFv) recombinant antibody fragment. In vitro mouse muscle twitch assays demonstrated the functional utility of this scFv extracted from tobacco for neutralizing the paralytic effects of BoNT/A at neuromuscular junctions. Based on the efficiency of the scFv capture process and the dose required to antidote a human being. 1-2 ha of this tobacco could yield up to 4 kg of scFv, which would be enough to contribute to the manufacture of 1,000,000 therapeutic doses of a monoclonal antibody (mAb) cocktail capable of neutralizing the effects of BoNT poisoning. Transgenic plants could provide an inexpensive production platform for expression of multiple mAbs toward the creation of polyclonal therapies (i.e. pooled mAbs) as the next improvement in recombinant antibody therapy. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2079 / 2086
页数:8
相关论文
共 50 条
[31]   Redirecting circulating antibodies via ligand-hapten conjugates eliminates target cells in vivo [J].
Lussow, AR ;
Buelow, R ;
Fanget, L ;
Peretto, S ;
Gao, L ;
Pouletty, P .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (04) :257-265
[32]   Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization [J].
Marks, JD .
MOVEMENT DISORDERS, 2004, 19 :S101-S108
[33]  
MIDDLEBROOK JL, 1997, MED ASPECTS CHEM BIO, V3
[34]  
MIKI B, 1999, BIOTECHNOL AGR FOR, V45, P336
[35]   PHARMACOKINETIC STUDY OF ANTI-INTERLEUKIN-6 (IL-6) THERAPY WITH MONOCLONAL-ANTIBODIES - ENHANCEMENT OF IL-6 CLEARANCE BY COCKTAILS OF ANTI-IL-6 ANTIBODIES [J].
MONTEROJULIAN, FA ;
KLEIN, B ;
GAUTHEROT, E ;
BRAILLY, H .
BLOOD, 1995, 85 (04) :917-924
[36]   Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody [J].
Nowakowski, A ;
Wang, C ;
Powers, DB ;
Amersdorfer, P ;
Smith, TJ ;
Montgomery, VA ;
Sheridan, R ;
Blake, R ;
Smith, LA ;
Marks, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11346-11350
[37]   Increasing expression of an anti-picloram single-chain variable fragment (ScFv) antibody and resistance to picloram in transgenic tobacco (Nicotiana tabacum) [J].
Olea-Popelka, F ;
McLean, MD ;
Horsman, J ;
Almquist, K ;
Brandle, JE ;
Hall, JC .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2005, 53 (17) :6683-6690
[38]   A strategy for the generation of specific human antibodies by directed evolution and phage display -: An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom [J].
Riaño-Umbarila, L ;
Juárez-González, VR ;
Olamendi-Portugal, T ;
Ortíz-León, M ;
Possani, LD ;
Becerril, B .
FEBS JOURNAL, 2005, 272 (10) :2591-2601
[39]   Antibodies and genetically engineered related molecules: Production and purification [J].
Roque, ACA ;
Lowe, CR ;
Taipa, MA .
BIOTECHNOLOGY PROGRESS, 2004, 20 (03) :639-654
[40]   Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomeation [J].
Ruha, AM ;
Curry, SC ;
Beuhler, M ;
Katz, K ;
Brooks, DE ;
Graeme, KA ;
Wallace, K ;
Gerkin, R ;
LoVecchio, F ;
Wax, P ;
Selden, B .
ANNALS OF EMERGENCY MEDICINE, 2002, 39 (06) :609-615